Brand Name Drug Negotiations Status
The pCPA is a part of the overall Canadian drug approval and reimbursement process. It starts with regulatory approval through Health Canada where drugs are evaluated for efficacy, quality and safety. Following a positive approval from Health Canada, all drugs then go through a health technology assessment for clinical and cost-effectiveness. In Canada there are two review boards, the Canadian Agency for Drugs and Technologies in Health (CADTH) which reviews common drugs through the Common Drug Review (CDR) and oncology drugs through the Pan-Canadian Oncology Drug Review (pCODR). In Quebec, drugs are reviewed through l’Institut national d’excellence en santé et en services sociaux (INESSS). For the majority of new drugs, the pCPA negotiation process begins once a recommendation is published by CADTH and/or INESSS.
| Product | Manufacturer | Status | Indication |
|---|---|---|---|
| Carvykti (ciltacabtagene autoleucel) | Janssen Inc. | Under consideration for negotiation | For the treatment of adult patients with multiple myeloma (MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment. |
| Rylaze (crisantaspase recombinant) | Jazz Pharmaceuticals Canada Inc. | Under consideration for negotiation | A component of a multi-agent chemotherapeutic regimen for the treatment of: Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase. |
| Lapelga (pegfilgrastrim) | Apobiologix, a Division of Apotex Inc. | Active Negotiation | To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug. |
| Trurapi (insulin aspart) | sanofi-aventis Canada Inc. | Active Negotiation |
• the treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin) • continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion |
| Camzyos (mavacamten) | Bristol Myers Squibb Canada Inc. | Under consideration for negotiation | Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients. |
| Tecartus (brexucabtagene autoleucel) | Gilead Sciences Canada Inc. | Active Negotiation | For treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) |
| Opdivo (nivolumab) | BRISTOL-MYERS SQUIBB CANADA | Active Negotiation | For the neoadjuvant treatment of adult patients with resectable NSCLC (tumours ≥4cm or node positive) when used in combination with platinum-doublet chemotherapy |
| Empaveli (pegcetacoplan) | Sobi Canada Inc. | Under consideration for negotiation | For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor |
| "TBC" (ranibizumab) | Teva Canada Inc. | Active Negotiation |
Treatment of: • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to diabetic macular edema (DME) • visual impairment due to macular edema secondary to retinal vein occlusion (RVO) • visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM) • visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy |
| Kerendia (finerenone) | Bayer Inc. | Under consideration for negotiation | adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Active Negotiation | For the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy |
| Pluvicto (lutetium vipivotide tetraxetan) | Advanced Accelerator Applications | Under consideration for negotiation | For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy. |
| Rybrevant (amivantamab) | Janssen Inc. | Under consideration for negotiation | For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy |
| Ultomiris (ravulizumab) | Alexion Pharma GMBH | Active Negotiation | Atypical hemolytic uremic syndrome |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Concluded with an LOI | for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) |
| Orladeyo (berotralstat) | BioCryst Pharmaceuticals Inc. | Under consideration for negotiation | hereditary angioedema |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | For the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy. |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Under consideration for negotiation | In combination with gemcitabine-based chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) |
| Yescarta (axicabtagene ciloleucel) | Gilead Sciences Canada Inc. | Under consideration for negotiation | for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy |
| Oxlumo (lumasiran) | Alnylam Netherlands B.V. | Under consideration for negotiation | primary hyperoxaluria type 1 |
| Dupixent (dupilumab) | sanofi-aventis Canada Inc. | Concluded with an LOI | Asthma |
| Dupixent (dupilumab) | sanofi-aventis Canada Inc. | Concluded with an LOI | atopic dermatitis |
| Saphnelo (anifrolumab) | AstraZeneca Canada Inc. | Active Negotiation | Systemic lupus erythematosus |
| Benlysta (belimumab) | GlaxoSmithKline Inc. | Active Negotiation | lupus nephritis |
| Ferriprox (deferiprone)) | Chiesi Canada Corporation | Under consideration for negotiation | For the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias |
| Ozurdex (dexamethasone) | AbbVie Corporation | Negotiations were not pursued | Diabetic Macular Edema |
| Beovu (brolucizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Diabetic Macular Edema |
| Nubeqa (Darolutamide) | Bayer Inc. | Under consideration for negotiation | For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel |
| Dayvigo (lemborexant) | Eisai Limited | Active Negotiation | Insomnia |
| Blood glucose test strips (blood glucose test strips) | Tykess Pharmaceuticals Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips ( blood glucose test strips) | Dex Medical Distribution Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Roche Diabetes Care, division of Hoffman-La Roche Ltd. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Bionime USA Corporation | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Pembrolizumab in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors express PD‐L1 (CPS ≥ 10) as determined by a validated test |
| Kimmtrak (tebentafusp) | Medison Pharma Canada Inc. | Active Negotiation | For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |
| Dificid (fidaxomicin) | Merck Canada Inc. | Active Negotiation | Clostridium difficile infection |
| Ruzurgi (Amifampridine) | Médunik Canada Inc. | Concluded with an LOI | Lambert-Eaton myasthenic syndrome (LEMS) |
| Radicava (edaravone) | Mitsubishi Tanabe Pharma Canada, Inc. | Active Negotiation | amyotrophic lateral sclerosis |
| Vyepti (eptinezumab) | Lundbeck Canada Inc. | Active Negotiation | Prevention of migraine |
| Zepzelca (lurbinectedin) | Jazz Pharmaceuticals Canada Inc. | Under consideration for negotiation | For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy |
| Wakix (pitolisant hydrochloride) | Paladin Labs Inc. | Concluded without agreement | For the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy |
| Blood glucose test strips (blood glucose test strips) | Tremblay Harrison Inc. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | sanofi-aventis Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Novo Biomedical Canada Ltd. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Auto Control Medical Inc | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD‐L1 (CPS ≥ 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab |
| Zeposia (ozanimod) | Celgene Inc. | Under consideration for negotiation | Ulcerative Colitis |
| Tremfya (guselkumab) | Janssen Inc. | Active Negotiation | Psoriatic Arthritis |
| Nucala (mepolizumab) | GlaxoSmithKline Inc. | Under consideration for negotiation | severe chronic rhinosinusitis with nasal polyps |
| Tezspire (tezepelumab) | AstraZeneca Canada Inc. | Under consideration for negotiation | severe asthma |
| Xydalba (dalbavancin) | Paladin Labs Inc. | Active Negotiation | acute bacterial skin and skin structure infections |
| Rymti (etanercept) | Lupin Pharma Canada Ltd. | Active Negotiation | ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis and polyarticular juvenile idiopathic arthritis |
| Vraylar (cariprazine) | AbbVie Corporation | Negotiations were not pursued | bipolar disorder |
| Palynziq (pegvaliase) | BioMarin Pharmaceutical Inc. | Under consideration for negotiation | Phenylketonuria |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection |
| Livtencity (maribavir) | Takeda Canada Inc. | Active Negotiation | post-transplant cytomegalovirus (CMV) infection/disease |
| Rozlytrek (Entrectinib) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | For the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals | Active Negotiation | For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory (RAI-R) or ineligible |
| Jardiance (empagliflozin) | Boehringer Ingelheim (Canada) Ltd. | Under consideration for negotiation | adjunct to standard of care therapy for the treatment of chronic heart failure in adults |
| Vabysmo (faricimab) | Hoffmann-La Roche Limited | Concluded with an LOI | diabetic macular edema (DME) |
| Minjuvi (tafasitamab) | Incyte Biosciences Canada Corporation | Negotiations were not pursued | in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant |
| Retevmo (selpercatinib) | Eli Lilly Canada Inc. | Concluded with an LOI | For the treatment of rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease. |
| Enhertu (trastuzumab deruxtecan) | AstraZeneca Canada Inc. | Active Negotiation | For the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Indicated as monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC |
| Verzenio (abemaciclib) | Eli Lilly Canada Inc. | Active Negotiation | in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ≥20% |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | For the adjuvant treatment of adult patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions |
| Gavreto (pralsetinib) | Hoffmann-La Roche Limited | Under consideration for negotiation | For the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Active Negotiation | For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)–positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance |
| Wegovy (semaglutide) | Novo Nordisk Canada Inc. | Negotiations were not pursued | chronic weight management |
| Jakavi (ruxolintib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | acute graft-versus-host disease |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | In combination with pembrolizumab, for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | in combination with Lenvatinib (Lenvima) for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | For the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery |
| Byooviz (ranibizumab) | Biogen Canada Inc. | Concluded with an LOI |
Treatment of: • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to diabetic macular edema (DME) • visual impairment due to macular edema secondary to retinal vein occlusion (RVO) • visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM) • visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy |
| Spinraza (nusinersen) | Biogen Canada Inc. | Negotiations were not pursued | spinal muscular atrophy (SMA) in patients aged 18 years or older |
| Tecentriq (atezolizumab) | Hoffmann-La Roche | Concluded with an LOI | Indicated as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations |
| Tepmetko (tepotinib) | EMD Serono Canada, a division of EMD Inc. | Active Negotiation | For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations |
| Jemperli (dostarlimab) | GlaxoSmithKline Inc. | Negotiations were not pursued | For the treatment of adult patients mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen |
| Cibinqo (abrocitinib) | Pfizer Canada ULC | Active Negotiation | moderate to severe atopic dermatitis |
| Poteligeo (mogamulizumab) | Kyowa Kirin Canada, Inc. | Active Negotiation | mycosis fungoides (MF), Sézary syndrome (SS) |
| Vabysmo (faricimab) | Hoffmann-La Roche Limited | Concluded with an LOI | neovascular (wet) age-related macular degeneration (nAMD) |
| Vraylar (cariprazine) | AbbVie Corporation | Concluded with an LOI | schizophrenia in adults |
| Kirsty (insulin aspart) | BGP Pharma ULC, d.b.a. Viatris Canada | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Brukinsa (zanubrutinib) | BeiGene, Ltd. | Negotiations were not pursued | For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. |
| Xpovio (selinexor) | Forus Therapeutics Inc. | Concluded with an LOI | For the treatment of adult patients, in combination with bortezomib (V) and dexamethasone (d), with multiple myeloma (MM) who have received at least one prior therapy. |
| Scemblix (asciminib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors |
| Vegzelma (bevacizumab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | For the treatment of: Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) – Glioblastoma |
| Inqovi (Decitabine-Cedazuridine) | Taiho Pharma Canada, Inc. | Concluded with an LOI | Treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups |
| Jakavi (ruxolintib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | chronic graft-versus-host disease |
| Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) | Amylyx Canada | Active Negotiation | amyotrophic lateral sclerosis (ALS) |
| Breyanzi (lisocabtagene maraleucel) | Celgene Inc. | Active Negotiation | Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma |
| Nexviazyme (avalglucosidase alfa) | sanofi-aventis Canada Inc. | Under consideration for negotiation | late-onset Pompe disease |
| Retevmo (selpercatinib) | Eli Lilly Canada Inc. | Concluded with an LOI | monotherapy treatment of rearranged during transfection (RET) fusion-positive differentiated thyroid carcinoma (DTC) in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | in combination with Lenvima, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | In combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC) |
| Vyndaqel (tafamidis) | Pfizer Canada ULC | Concluded with an LOI | Cardiomyopathy due to transthyretin-mediated amyloidosis |
| Firdapse (amifampridine phosphate) | KYE Pharmaceuticals Inc. | Concluded with an LOI | Lambert-Eaton Myasthenic Syndrome (LEMS) in adults |
| pdp-Amlodipine (amlodipine) | Pendopharm, a division of Pharmascience Inc. | Concluded with an LOI | Treatment of mild to moderate essential hypertension and management of chronic stable angina |
| Arazlo (tazarotene) | Bausch Health, Canada Inc. | Concluded with an LOI | acne vulgaris |
| Bryhali (halobetasol propionate) | Bausch Health, Canada Inc. | Concluded with an LOI | corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis |
| Rinvoq (upadacitinib) | AbbVie Corporation | Active Negotiation | atopic dermatitis |
| Elonox and Elonox HP (enoxaparin sodium) | Fresenius Kabi Canada Ltd. | Concluded with an LOI | Prevention or treatment of thrombosis and cardiovascular conditions |
| Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation in patients aged 6 years and older |
| Libtayo (cemiplimab) | sanofi-aventis Canada Inc. | Active Negotiation | For the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC |
| Osphena (ospemifene) | Duchesnay Inc. | Concluded without agreement | dyspareunia and/or vaginal dryness |
| Nypozi (filgrastim) | Tanvex BioPharma USA, Inc. | Concluded with an LOI | Prevention or treatment of neutropenia in various indications |
| Semglee (Insulin Glargine) | BGP Pharma ULC, d.b.a. Viatris Canada | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | ForaCare Technology Canada, Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Skymed Monitors Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | MediSure Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | LifeScan Canada ULC | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | I-Sens, Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | BTNX Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Ascensia Diabetes Care | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Spirit Healthcare Group | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Abbott Diabetes Care | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Retevmo (selpercatinib) | Eli Lilly Canada Inc. | Concluded with an LOI | indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients |
| Qinlock (ripretinib) | Medison Pharma Canada Inc. | Concluded with an LOI | For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib |
| Insulin pumps and pump supplies (insulin pumps and pump supplies) | Insulet Canada Corporation | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Insulin pumps and pump supplies (Insulin pumps and pump supplies) | Ypsomed Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Insulin pumps and pump supplies (Insulin pumps and pump supplies) | Medtronic Canada | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Intrarosa (prasterone) | Lupin Pharma Canada Ltd. | Concluded without agreement | postmenopausal vulvovaginal atrophy |
| Tavalisse (fostamatinib) | Medison Pharma Canada | Negotiations were not pursued | chronic immune thrombocytopenia |
| Bimzelx (bimekizumab) | UCB Canada Inc. | Concluded with an LOI | psoriasis, moderate to severe plaque |
| Pemazyre (pemigatinib) | Incyte Biosciences Canada Corporation | Negotiations were not pursued | adults with previously treated, unresectable locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Concluded without agreement | Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) |
| Adtralza (tralokinumab) | LEO Pharma Inc. | Negotiations were not pursued | atopic dermatitis |
| Myinfla (colchicine) | Pendopharm, a division of Pharmascience Inc. | Negotiations were not pursued | atherothrombotic events in coronary artery disease |
| Ngenla (somatrogon) | Pfizer Canada ULC | Concluded with an LOI | growth hormone deficiency |
| Libtayo (cemiplimab) | Sanofi Genzyme | Active Negotiation | For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor. |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Opdivo — in combination with fluoropyrimidine- and platinum-containing chemotherapy — for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients |
| Leqvio (inclisiran) | Novartis Pharmaceuticals Canada Inc. | Under consideration for negotiation | Primary hypercholesterolemia (non-familial and heterozygous familial) |
| Ultomiris (ravulizumab) | Alexion Pharma Canada Corp. | Active Negotiation | Paroxysmal nocturnal hemoglobinuria (PNH) |
| Bijuva (estradiol and progesterone) | Knight Therapeutics Inc. | Active Negotiation | vasomotor symptoms associated with menopause |
| Waymade-Trientine (trientine hydrochloride) | Waymade Canada Inc | Concluded with an LOI | Wilson's Disease |
| Vectibix (panitumumab) | Amgen Canada Inc. | Concluded with an LOI | For the treatment of metastatic colorectal cancer |
| Phesgo SC (perjeta and herceptin) | HOFFMANN-LA ROCHE LIMITED | Concluded without agreement | For the first-line treatment of patients with HER2-positive metastatic breast cancer |
| Darzalex SC (Daratumumab) | Janssen Inc. | Concluded with an LOI | Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. |
| Trodelvy (sacituzumab govitecan) | Gilead Sciences Canada Inc. | Concluded with an LOI | For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease |
| Sarclisa (Isatuximab) | Sanofi Genzyme | Concluded with an LOI | In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy |
| Piqray (alpelisib) | Novartis Pharmaceuticals Canada Inc. | Concluded without agreement | In combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT) |
| Perjeta (pertuzumab) | HOFFMANN-LA ROCHE LIMITED | Under consideration for negotiation | In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive) |
| Increlex (mecasermin) | Ipsen Biopharmaceuticals Canada, Inc. | Concluded with an LOI | severe primary insulin-like growth factor-1 deficiency |
| Dojolvi (triheptanoin) | Ultragenyx Canada Inc. | Concluded with an LOI | long-chain fatty acid oxidation disorders |
| Trazimera (trastuzumab) | Pfizer Canada ULC | Concluded with an LOI | Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Herzuma (trastuzumab) | Teva Canada Limited | Concluded with an LOI | Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Ogivri (trastuzumab) | BGP Pharma ULC | Concluded with an LOI | Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Kanjinti (trastuzumab) | Amgen Canada Inc. | Concluded with an LOI | Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Imvexxy (estradiol) | Knight Therapeutics Inc. | Concluded with an LOI | postmenopausal moderate to severe dyspareunia |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | Indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations |
| Opdivo-Yervoy (nivolumab-ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations |
| Kyprolis (carfilzomib) | Amgen Canada Inc. | Concluded with an LOI | Treatment of multiple myeloma (including relapsed) |
| Padcev (enfortumab vedotin) | Seagen Canada Inc. | Concluded with an LOI | For the treatment of adult patients with unresectable, locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy. |
| Ontruzant (trastuzumab) | Organon Canada Inc. | Concluded with an LOI | Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC) |
| Mvasi (bevacizumab) | Amgen Canada Inc. | Concluded with an LOI | first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen |
| Opsynvi (macitentan and tadalafil) | Janssen Inc. | Concluded without agreement | pulmonary arterial hypertension |
| Emgality (galcanezumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Prevention of migraine |
| Reblozyl (luspatercept) | Celgene Inc. | Concluded with an LOI | myelodysplastic syndromes associated anemia |
| Brukinsa (zanubrutinib) | BeiGene, Ltd. | Concluded with an LOI | Waldenström’s macroglobulinemia |
| Ledaga (chlormethine hydrochloride) | Recordati Rare Diseases Canada Inc. | Concluded without agreement | For the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) |
| Evenity (romosozumab) | Amgen Canada Inc. | Active Negotiation | osteoporosis |
| MAR-Trientine (trientine) | Marcan Pharmaceuticals Inc. | Concluded with an LOI | Wilson's Disease |
| Tukysa ( tucatinib) | Seagen Canada Inc. | Concluded with an LOI | Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination |
| Abecma (idecabtagene vicleucel) | Celgene Inc. | Under consideration for negotiation | For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment |
| Zaxine (rifaximin) | Lupin Pharma Canada Limited | Concluded with an LOI | Hepatic Encephalopathy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT |
| Aybintio (bevacizumab) | Organon Canada Inc. | Concluded with an LOI | For the treatment of: Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) – Glioblastoma |
| Onureg (azacitidine) | Celgene Inc. | Concluded with an LOI | Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT) |
| Abrilada (adalimumab) | Pfizer Canada ULC | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Yuflyma (adalimumab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Kirsty (insulin aspart) | BGP Pharma ULC, d.b.a. Viatris Canada | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Givlaari (givosiran) | Alnylam Netherlands B.V. | Concluded with an LOI | acute hepatic porphyria |
| Xeomin (incobotulinumtoxinA) | Merz Therapeutics Canada | Concluded without agreement | chronic sialorrhea associated with neurological disorders |
| Perseris (risperidone) | HLS Therapeutics Inc. | Concluded without agreement | Schizophrenia |
| Inqovi (Decitabine-Cedazuridine) | Taiho Pharma Canada, Inc. | Concluded without agreement | Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups |
| Saxenda (liraglutide) | Novo Nordisk Canada Inc. | Negotiations were not pursued | chronic weight management |
| Vitrakvi (larotrectinib) | Bayer Inc. | Concluded with an LOI | For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options. |
| Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate) | ASTRAZENECA CANADA INC | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation |
| Vyxeos (daunorubicin and cytarabine) | Jazz Pharmaceuticals Canada Inc. | Concluded with an LOI | For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). |
| Tecartus (brexucabtagene autoleucel) | Gilead Sciences Canada Inc. | Concluded with an LOI | For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) |
| Evrysdi (risdiplam) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | Spinal Muscular Atrophy |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Psoriatic Arthritis |
| Entuzity KwikPen (human insulin) | Eli Lilly Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Jorveza (budesonide) | AVIR Pharma Inc. | Concluded without agreement | eosinophic esophagitis (maintenance) |
| Venclexta (venetoclax) | AbbVie Corporation | Negotiations were not pursued | Venclexta in combination with low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Opdivo-Yervoy (nivolumab-ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Concluded with an LOI | IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) |
| Braftovi (encorafenib) | Pfizer Canada ULC | Concluded with an LOI | Braftovi in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy, |
| Braftovi/Mektovi (encorfenib/binimetinib) | Pfizer Canada ULC | Concluded with an LOI | Braftovi (encorafenib) and Mektovi (binimetinib), in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test |
| Unituxin (dinutuximab) | United Therapeutics | Concluded with an LOI | high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor |
| Inrebic (fedrantinib) | Celgene Inc. | Concluded with an LOI | Treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib |
| Zeposia (ozanimod) | Celgene Inc. | Negotiations were not pursued | Relapsing-Remitting Multiple Sclerosis |
| Rybelsus (semaglutide) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Insulin pumps and pump supplies (Insulin pumps and pump supplies) | Tandem Diabetes Care Canada, Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Veltassa (patiromer) | Otsuka Canada Pharmaceuticals Inc. | Concluded without agreement | hyperkalemia |
| Reblozyl (luspatercept) | Celgene Inc. | Concluded with an LOI | beta-thalassemia associated anemia |
| Dupixent (dupilumab) | Sanofi Genzyme | Concluded without agreement | Asthma |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded without agreement | Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease |
| Ilumya (tildrakizumab) | Sun Pharma Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Simlandi (adalimumab) | Jamp Pharma Corporation | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Corzyna (ranolazine) | KYE Pharmaceuticals Inc. | Concluded without agreement | angina pectoris |
| Zejula (Niraparib) | GlaxoSmithKline Inc. | Concluded with an LOI | Ovarian Cancer: Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy |
| Odomzo (sonidegib) | Sun Pharma Canada Inc. | Negotiations were not pursued | Basal Cell Carcinoma (BCC): For the treatment of adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery |
| Bambevi (bevacizumab) | Apotex Inc. | Concluded with an LOI | Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma |
| Polivy (Polatuzumab Vedotin) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | In combo with bendamustine & rituximab is indicated for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, who are not eligible for autologous stem cell transplant & have received at least one prior therapy. |
| Alunbrig (brigatinib) | Takeda Canada Inc. | Concluded with an LOI | For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Monotherapy for the treatment of adult patients with mCRPC & deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA |
| Rozlytrek (Entrectinib) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | ROS1-positive Non-Small Cell Lung Cancer |
| Ruzurgi (Amifampridine) | Médunik Canada Inc. | Concluded without agreement | Lambert-Eaton myasthenic syndrome (LEMS) |
| Enspryng (satralizumab) | Hoffmann-La Roche Limited | Concluded with an LOI | neuromyelitis optica spectrum disorders (NMOSD) |
| Osnuvo (teriparatide) | AVIR Pharma Inc. | Concluded with an LOI | osteoporosis |
| Sarclisa (Isatuximab) | Sanofi Genzyme | Concluded with an LOI | Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. |
| Remsima SC (infliximab) | Celltrion Healthcare Canada Ltd. | Concluded without agreement | Rheumatoid Arthritis |
| Abevmy (bevacizumab) | BGP Pharma ULC | Concluded with an LOI | Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma |
| Bavencio (avelumab) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy |
| Ajovy (fremanezumab) | Teva Canada Inc. | Concluded with an LOI | prevention of migraine in adults |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Calquence (Acalabrutinib) | ASTRAZENECA CANADA INC | Concluded with an LOI | Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate |
| Calquence (Acalabrutinib) | ASTRAZENECA CANADA INC | Concluded with an LOI | Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. |
| Kynmobi (apomorphine hydrochloride) | Sunovion Pharmaceuticals Canada Inc. | Concluded with an LOI | Parkinson's disease |
| Kesimpta (ofatumumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Relapsing-Remitting Multiple Sclerosis |
| Ofev (nintedanib) | Boehringer Ingelheim (Canada) Ltd. | Concluded with an LOI | Chronic fibrosing interstitial lung diseases |
| Darzalex SC (Daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma |
| Daurismo (Glasdegib) | Pfizer Canada ULC | Negotiations were not pursued | Acute Myeloid Leukemia (AML) |
| pdp-levETIRAcetam (levetiracetam) | Pendopharm, a division of Pharmascience Inc. | Concluded with an LOI | Epilepsy |
| Zolgensma (onasemnogene abeparvovec) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Tecentriq and bevacizumab (Atezolizumab & Bevacizumab) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy. |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Forxiga (dapagliflozin) | AstraZeneca Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Entyvio (SC) (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Crohn's disease |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Hodgkin's Lymphoma |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides) |
| Spravato (esketamine hydrochloride) | JANSSEN INC | Negotiations were not pursued | Major Depressive Disorder |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL) |
| Riabni (rituximab) | Amgen Canada Inc. | Concluded with an LOI | Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) |
| Inclunox (enoxaparin) | Sandoz Canada Inc. | Concluded with an LOI | Deep vein thrombosis (treatment and prevention) |
| Noromby (enoxaparin) | Juno Pharmaceuticals Corp. | Concluded with an LOI | Deep vein thrombosis (treatment and prevention) |
| Nyvepria (pegfilgrastim) | Pfizer Canada ULC | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Trurapi (insulin aspart) | sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Foquest (methylphenidate) | Elvium Life Sciences | Concluded with an LOI | Attention-deficit/hyperactivity disorder (ADHD) |
| Suboxone (film) (buprenorphine and naloxone) | Indivior UK Limited | Concluded with an LOI | Opioid drug dependence |
| Atectura Breezhaler (indacaterol /mometasone furoate) | Valeo Pharma Inc. | Concluded with an LOI | Asthma |
| Enerzair Breezhaler (indacaterol/glycopyrronium/mometasone furoate) | Valeo Pharma Inc. | Concluded with an LOI | Asthma |
| Luxturna (voretigene neparvovec) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Vision loss, inherited retinal dystrophy |
| Hadlima (adalimumab) | Merck | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Idacio (adalimumab) | Fresenius Kabi Canada Ltd. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Hyrimoz (adalimumab) | Sandoz Canada Inc. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Amgevita (adalimumab) | AMGEN CANADA INC | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Hulio (adalimumab) | BGP Pharma ULC | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Jorveza (budesonide) | AVIR Pharma Inc. | Concluded without agreement | eosinophilic esophagitis (induction) |
| Duobrii (Halobetasol propionate and tazarotene) | Bausch Health, Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Nexplanon (etonogestrel) | Merck Canada Inc. | Concluded with an LOI | prevention of pregnancy |
| Soliris (eculizumab) | Alexion Pharma GMBH | Concluded without agreement | Myasthenia Gravis |
| Zejula (Niraparib) | GlaxoSmithKline Inc. | Concluded with an LOI | Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | Metastatic Castration Sensitive Prostate Cancer |
| Cablivi (caplacizumab) | sanofi-aventis Canada Inc. | Negotiations were not pursued | acquired thrombotic thrombocytopenic purpura (aTTP) |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Concluded with an LOI | Multiple Indications |
| Tecentriq & Avastin (Atezolizumab & Bevacizumab) | HOFFMANN-LA ROCHE LIMITED | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Aimovig (erenumab) | NOVARTIS PHARMACEUTICALS CANADA INC | Concluded without agreement | migraine, chronic |
| Vocabria and Cabenuva (cabotegravir and rilpivirine) | VIIV HEALTHCARE ULC | Concluded with an LOI | HIV Infection |
| Mayzent (siponimod) | NOVARTIS PHARMACEUTICALS CANADA INC | Concluded with an LOI | Secondary progressive multiple sclerosis (SPMS) |
| Vascepa (icosapent ethyl) | HLS Therapeutics Inc. | Concluded with an LOI | Ischemic events in statin-treated patients |
| Stelara (ustekinumab) | Janssen Inc. | Concluded without agreement | Ulcerative Colitis |
| Soliris (eculizumab) | Alexion Pharma GMBH | Concluded without agreement | Neuromyelitis optica spectrum disorder (NMOSD) |
| Darzalex SC (Daratumumab) | Janssen Inc. | Concluded without agreement | Multiple Myeloma |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Cuvposa (Glycopyrrolate) | Medexus Pharmaceuticals, Inc. | Concluded with an LOI | For the reduction of pediatric chronic severe drooling (neurologic) |
| Xospata (Gilteritinib) | Astellas Pharma Inc. | Concluded with an LOI | Acute Myeloid Leukemia |
| Aermony Respiclick (fluticasone propionate) | Teva Canada Limited | Concluded with an LOI | Asthma |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation |
| Contrave (naltrexone hydrochloride and bupropion hydrochloride) | Bausch Health, Canada Inc. | Negotiations were not pursued | Chronic weight management |
| Nubeqa (Darolutamide) | Bayer Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Erleada (apalutamide) | Janssen Inc. | Concluded with an LOI | Metastatic Castration-Sensitive Prostate Cancer |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals | Concluded with an LOI | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Crysvita (burosumab) | Ultragenyx Canada Inc. | Concluded with an LOI | X-Linked Hypophosphatemia |
| Entyvio (SC) (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Ulcerative Colitis |
| Dupixent (dupilumab) | Sanofi Genzyme | Concluded with an LOI | Atopic dermatitis |
| Beovu (brolucizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Age-Related Macular Degeneration |
| Benlysta (belimumab) | GlaxoSmithKline Inc. | Active Negotiation | Systemic lupus erythematosus |
| Kisqali (with fulvestrant) (ribociclib with fulvestrant) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Allerject (epinephrine) | Kaleo Inc | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Otezla (apremilast) | Amgen Canada Inc. | Concluded without agreement | Psoriatic Arthritis |
| Otezla (apremilast) | Amgen Canada Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Avsola (infliximab) | Amgen Canada Inc. | Concluded with an LOI | Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis |
| Nivestym (filgrastim) | Pfizer Canada ULC | Concluded with an LOI | Prevention or treatment of neutropenia in various indications |
| Ziextenzo (pegfilgrastim) | Sandoz Canada | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Redesca (enoxaparin) | Valeo Pharma Inc. | Concluded with an LOI | Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism |
| Kanjinti (trastuzumab) | Amgen Canada Inc. | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Envarsus PA (tacrolimus) | Paladin Labs Inc. | Concluded with an LOI | prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients |
| Onstryv (safinamide) | Valeo Pharma Inc. | Concluded with an LOI | Parkinson's disease |
| Monoferric (iron (iii) isomaltoside 1000) | Pharmacosmos A/S | Concluded with an LOI | iron deficiency anemia |
| Lokelma (sodium zirconium cyclosilicate) | AstraZeneca Canada Inc. | Negotiations were not pursued | hyperkalemia |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded without agreement | Ankylosing spondylitis |
| Vyndaqel (tafamidis) | Pfizer Canada ULC | Concluded with an LOI | transthyretin-mediated amyloidosis |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Rheumatoid Arthritis |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Concluded with an LOI | metastatic Gastric Cancer |
| Riximyo (rituximab) | Sandoz Canada | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Ruxience (rituximab) | Pfizer Canada ULC | Concluded with an LOI | Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded with an LOI | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Baqsimi (glucagon) | Eli Lilly Canada Inc. | Concluded with an LOI | severe hypoglycemia |
| Admelog (insulin lispro) | sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Negotiations were not pursued | Non-Small Cell Lung Cancer (ALK+) |
| Rydapt (midostaurin) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Systemic Mastocytosis |
| Mylotarg (gemtuzumab ozogamicin) | Pfizer Canada ULC | Concluded with an LOI | Acute Myeloid Leukemia |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | renal cell carcinoma |
| Nerlynx (neratinib) | Knight Therapeutics | Negotiations were not pursued | Hormone Receptor-Positive Breast Cancer |
| Cimzia (certolizumab pegol) | UCB Canada Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Takhzyro (lanadelumab) | Shire Pharma Canada ULC | Concluded with an LOI | Hereditary Angioedema |
| Revestive (teduglutide) | Shire Pharma Canada ULC | Concluded with an LOI | Short Bowel Syndrome (SBS) |
| Verkazia (cyclosporine) | Santen Incorporated | Concluded with an LOI | severe vernal keratoconjunctivitis |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| Mezera (mesalazine) | AVIR Pharma Inc. | Concluded with an LOI | Ulcerative Colitis |
| Kadcyla (trastuzumab emtansine) | Hoffmann-La Roche | Concluded with an LOI | early breast cancer |
| Darzalex (daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Squamous Non-Small Cell Lung Cancer |
| Tecentriq (atezolizumab) | Hoffmann-La Roche | Concluded with an LOI | For the treatment of the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Trintellix (vortioxetine) | Lundbeck Canada Inc. | Concluded with an LOI | Major Depressive Disorder |
| Xultophy (insulin degludec/liraglutide) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Dovato (dolutegravir/lamivudine) | ViiV Healthcare | Concluded with an LOI | HIV Infection |
| Iluvien (fluocinolone acetonide) | Knight Therapeutics | Negotiations were not pursued | Diabetic Macular Edema |
| Emerade (epinephrine bitartrate) | Bausch Health, Canada Inc. | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Bosulif (bosutinib) | Pfizer Canada ULC | Concluded with an LOI | Chronic Myeloid Leukemia |
| Olumiant (baricitinib) | Eli Lilly Canada Inc. | Concluded with an LOI | Rheumatoid Arthritis |
| Orfadin Oral Suspension (nitisinone) | Sobi Canada Inc. | Concluded without agreement | Hereditary Tyrosinemia Type 1 |
| Onpattro (patisiran) | Alnylam Netherlands B.V. | Concluded with an LOI | hereditary transthyretin-mediated amyloidosis |
| Tegsedi (inotersen) | Akcea Therapeutics Inc. | Concluded with an LOI | hereditary transthyretin-mediated amyloidosis |
| Truxima (rituximab) | Teva Canada Limited | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Vitrakvi (larotrectinib) | Bayer Inc. | Negotiations were not pursued | Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours |
| Pomalyst (pomalidomide) | Celgene Inc. | Negotiations were not pursued | Multiple Myeloma (Relapsed) |
| Idhifa (enasidenib) | Celgene Inc. | Under consideration for negotiation | Acute Myeloid Leukemia |
| Revlimid (lenalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Sublocade (buprenorphine) | Indivior UK Limited | Concluded with an LOI | Opioid Use Disorder |
| Cystadrops (cysteamine) | Recordati Canada | Concluded with an LOI | corneal cystine crystal deposits |
| Libtayo (cemiplimab) | Sanofi Genzyme | Concluded with an LOI | Cutaneous Squamous Cell Carcinoma |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Darzalex (daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma (newly diagnosed) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded without agreement | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Alunbrig (brigatinib) | Takeda Canada Inc. | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Ninlaro (ixazomib) | Takeda Canada Inc. | Negotiations were not pursued | Multiple Myeloma |
| Verzenio (abemaciclib) | Eli Lilly Canada Inc. | Concluded without agreement | Advanced or Metastatic Breast Cancer |
| Vizimpro (dacomitinib) | Pfizer Canada ULC | Concluded without agreement | Non-Squamous Non-Small Cell Lung Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Negotiations were not pursued | Metastatic Urothelial Carcinoma (first line) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Venclexta/rituximab (venetoclax/rituximab) | AbbVie Corporation | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Xalkori (crizotinib) | Pfizer Canada ULC | Concluded with an LOI | ROS1-positive advanced Non-Small Cell Lung Cancer |
| Ibrance/fulvestrant (palbociclib/fulvestrant) | Pfizer Canada ULC | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Trazimera (trastuzumab) | Pfizer Canada ULC | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Herzuma (trastuzumab) | Teva Canada Limited | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Ogivri (trastuzumab) | BGP Pharma ULC | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Opsumit (macitentan) | Actelion Pharmaceuticals Ltd. | Concluded with an LOI | Pulmonary Arterial Hypertension |
| Brilinta (ticagrelor) | AstraZeneca Canada Inc. | Concluded with an LOI | secondary prevention of atherothrombotic events |
| Triamcinolone Hexacetonide (triamcinolone hexacetonide) | Medexus Pharmaceuticals, Inc. | Concluded with an LOI | Rheumatoid Arthritis |
| Skyrizi (risankizumab) | AbbVie Corporation | Concluded with an LOI | Plaque psoriasis |
| Vyzulta (latanoprostene bunod) | Bausch Health, Canada Inc. | Concluded with an LOI | Open-angle Glaucoma |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) |
| Folotyn (pralatrexate) | Servier Canada Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Botox (onabotulinumtoxin a) | Allergan Inc. | Concluded without agreement | migraine, chronic |
| Xermelo (telotristat) | Ipsen Biopharmaceuticals | Negotiations were not pursued | carcinoid syndorme |
| Jublia (efinaconazole) | Bausch Health, Canada Inc. | Negotiations were not pursued | onychomycosis |
| Pifletro (doravirine) | Merck Canada Inc. | Concluded with an LOI | HIV Infection |
| Delstrigo (doravirine/lamuvidine/tenofovir disoproxil fumarate) | Merck Canada Inc. | Concluded with an LOI | HIV Infection |
| Cresemba (isavuconazole) | AVIR Pharma Inc. | Concluded with an LOI | Treatment of invasive aspergillosis and mucormycosis |
| Unituxin (dinutuximab) | United Therapeutics | Concluded with an LOI | neuroblastoma |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Negotiations were not pursued | Hodgkin's Lymphoma |
| Radicava (edaravone) | Mitsubishi Tanabe Pharma Canada, Inc. | Concluded with an LOI | amyotrophic lateral sclerosis |
| Eucrisa (crisaborole) | Pfizer Canada ULC | Negotiations were not pursued | Atopic dermatitis |
| Brineura (cerliponase alfa) | BioMarin Pharmaceutical Inc. | Concluded with an LOI | neuronal ceroid lipofuscinosis type 2 |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation |
| Zirabev (bevacizumab) | Pfizer Canada ULC | Concluded with an LOI | Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer |
| Spinraza (nusinersen) | Biogen Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Xeljanz (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Ulcerative Colitis |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals | Concluded with an LOI | renal cell carcinoma |
| Mvasi (bevacizumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer |
| Ella (ulipristal acetate) | Allergan Inc. | Concluded with an LOI | prevention of pregnancy |
| Segluromet (ertugliflozin/metformin hydrochloride) | Merck Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Steglatro (ertugliflozin) | Merck Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Fulphila (pegfilgastrim) | BGP Pharma ULC | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Xeljanz XR (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Rheumatoid Arthritis |
| Humira (citrate-free) (adalimumab citrate-free) | AbbVie Corporation | Concluded without agreement | Multiple Indications |
| Ozempic (semaglutide) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Herceptin SC (trastuzumab) | Hoffmann-La Roche | Concluded without agreement | breast cancer |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | first-line treatment of locally advanced or metastatic non-small cell cell lung cancer (NSCLC) |
| Lenvima (lenvatinib) | Eisai Limited | Negotiations were not pursued | advanced or metastatic, clear-cell renal cell carcinoma |
| Harvoni (ledipasvir/sofosbuvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Velphoro (sucroferric oxyhydroxide) | Vifor Fresenius Medical Care Renal Pharma | Concluded with an LOI | Hyperphosphatemia, end-stage renal disease |
| Soliqua (lixisenatide/insulin glargine) | sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Perjeta/Herceptin (pertuzumab/trastuzumab) | Hoffmann-La Roche | Negotiations were not pursued | early breast cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Negotiations were not pursued | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Daklinza (daclatasvir) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Januvia (sitagliptin phosphate) | Merck Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Yervoy/Opdivo (nivolumab/ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | renal cell carcinoma |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Negotiations were not pursued | Follicular Lymphoma |
| Erleada (apalutamide) | Janssen Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Xarelto (rivaroxaban) | Bayer Inc. | Concluded with an LOI | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. |
| Ozurdex (dexamethasone) | Negotiations were not pursued | Diabetic Macular Edema | |
| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Fibristal (ulipristal acetate) | Allergan Inc. | Concluded with an LOI |
Intermittent treatment of moderate to severe signs and symptoms of uterine fibroids uterine fibroids |
| Alecensaro (alectinib) | Hoffmann-La Roche | Concluded with an LOI | Non-Small Cell Lung Cancer (First Line) |
| Praluent (alirocumab) | sanofi-aventis Canada Inc. | Concluded without agreement | Atherosclerotic cardiovascular disease |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Negotiations were not pursued | Cystic Fibrosis, F508del CFTR mutation |
| Arbesda RespiClick (fluticasone propionate/salmeterol xinafoate) | Teva Canada Limited | Concluded without agreement | Asthma |
| Aermony Respiclick (fluticasone propionate) | Teva Canada Limited | Concluded without agreement | Asthma |
| Viberzi (eluxadoline) | Allergan Inc. | Negotiations were not pursued | Irritable Bowel Syndrome |
| Kanuma (sebelipase alfa) | Alexion Pharma GMBH | Concluded with an LOI | Lysosomal acid lipase deficiency |
| Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) | GlaxoSmithKline Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Mavenclad (cladribine) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Relapsing-Remitting Multiple Sclerosis |
| Nucynta (tapentadol hydrochloride) | Paladin Labs Inc. | Negotiations were not pursued | Pain, severe |
| Fasenra (benralizumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Eosinophilic Asthma |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Lower Limb Spasticity |
| Nitisinone (nitisinone) | Cycle Pharmaceuticals Ltd. | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Psoriatic Arthritis |
| Duodopa (levodopa/carbidopa) | AbbVie Corporation | Concluded with an LOI | Parkinson's disease |
| Probuphine (buprenorphine) | Knight Therapeutics | Concluded with an LOI | Opioid Use Disorder |
| Ozanex (ozenoxacin) | Ferrer Internacional | Negotiations were not pursued | Impetigo |
| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) | Janssen Inc. | Concluded without agreement | HIV infection |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer |
| Besponsa (inotuzumab ozogamicin) | Pfizer Canada ULC | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Tecentriq (atezolizumab) | Hoffmann-La Roche | Concluded with an LOI | Non-small Cell Lung Cancer |
| Dupixent (dupilumab) | Sanofi Genzyme | Concluded with an LOI | Atopic dermatitis |
| Lapelga (pegfilgrastrim) | Apobiologix | Concluded with an LOI | Febrile Neutropenia |
| Siliq (brodalumab) | Valeant Canada | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Prevymis (letermovir) | Merck Canada Inc. | Concluded with an LOI | Cytomegalovirus infection prophylaxis |
| Juluca (dolutegravir/rilpivirine) | ViiV Healthcare | Concluded with an LOI | HIV infection |
| Akynzeo (netupitant/palonosetron) | Purdue Pharma | Concluded with an LOI | Nausea and vomiting (chemotherapy induced) prevention |
| Toujeo (insulin glargine injection) | sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Concluded with an LOI | Chronic lymphocytic leukemia |
| Kevzara (sarilumab) | sanofi-aventis Canada Inc. | Concluded with an LOI | Rheumatoid Arthritis |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Upper Limb Spasticity |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Cervical dystonia |
| Enstilar (calcipotriol/betamethasone) | LEO Pharma Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Classic Hodgkin's Lymphoma |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Lartruvo (olaratumab) | Eli Lilly Canada Inc. | Concluded without agreement | Advanced Soft Tissue Sarcoma |
| Stivarga (regorafenib) | Bayer Inc. | Concluded with an LOI | Unresectable Hepatocellular Carcinoma |
| Alecensaro (alectinib) | Hoffmann-La Roche | Concluded with an LOI | Locally advanced or metastatic non-small cell lung cancer |
| Vectibix (panitumumab) | Amgen Canada Inc. | Negotiations were not pursued | Left Sided Metastatic Colorectal Cancer |
| Bavencio (avelumab) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Metastatic Merkel Cell Carcinoma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Metastatic Urothelial Carcinoma |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Hodgkin's Lymphoma |
| Ocrevus (ocrelizumab) | Hoffmann-La Roche | Concluded with an LOI | Primary Progressive Multiple Sclerosis |
| MDK-Nitisinone (nitisinone) | MendeliKABS Inc | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Monoprost (latanoprost) | Laboratoires Thea | Concluded without agreement | Glaucoma and Ocular Hypertension |
| Actemra (tocilizumab) | Hoffmann-La Roche | Concluded with an LOI | Giant Cell Arteritis |
| Vemlidy (tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded without agreement | Hepatitis B |
| Ilaris (canakinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Systemic juvenile idiopathic arthritis |
| Renflexis (infliximab) | Merck Canada Inc. | Concluded with an LOI | Rheumatic Conditions |
| Izba (travoprost) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Open-angle Glaucoma |
| Rexulti (brexpiprazole) | Otsuka Canada Pharmaceuticals | Concluded with an LOI | Schizophrenia |
| Galafold (migalastat) | Amicus Therapeutics | Concluded with an LOI | Fabry's Disease |
| Fiasp (insulin aspart) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Pomalyst (pomalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Mictoryl Pediatric (propiverine hydrochloride) | Duchesnay Inc. | Concluded with an LOI | Overactive bladder |
| Jevtana (cabazitaxel) | sanofi-aventis Canada Inc. | Concluded with an LOI | Castrate resistant metastatic prostate cancer |
| Rosiver (ivermectin) | Galderma Canada Inc. | Concluded without agreement | Rosacea |
| Rydapt (midostaurin) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Acute Myeloid Leukemia |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Concluded with an LOI | Follicular Lymphoma |
| Orfadin (nitisinone) | Sobi Canada Inc. | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Tremfya (guselkumab) | Janssen Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Procysbi (cysteamine bitartrate) | Horizon Therapeutics Ireland DAC | Concluded with an LOI | Nephropathic cystinosis |
| Maviret (glecaprevir/pibrentasvir) | AbbVie Corporation | Concluded with an LOI | Chronic Hepatitis C |
| Movapo (apomorphine hydrochloride) | Paladin Labs Inc. | Concluded with an LOI | Parkinson's disease |
| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Spinraza (nusinersen) | Biogen Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Zykadia (ceritinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Viacoram (perindopril arginine/amlodipine) | Servier Canada Inc. | Concluded without agreement | Hypertension |
| Adlyxine (lixisenatide) | sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Repatha (evolocumab) | Amgen Canada Inc. | Concluded without agreement | Primary hyperlipidemia and mixed dyslipidemia |
| Ocrevus (ocrelizumab) | Hoffmann-La Roche | Concluded with an LOI | multiple sclerosis, relapsing |
| Tresiba (insulin degludec) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Stivarga (regorafenib) | Bayer Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| VPRIV (velaglucerase) | Shire Pharma Canada ULC | Concluded with an LOI | Gaucher disease |
| Elelyso (taliglucerase alfa) | Pfizer Canada ULC | Concluded with an LOI | Gaucher disease |
| Cerezyme (imiglucerase) | Sanofi Genzyme Canada | Concluded without agreement | Gaucher disease |
| Kyleena (levonorgestrel) | Bayer Inc. | Concluded with an LOI | Conception Control |
| Invega Trinza (paliperidone palmitate) | Janssen Inc. | Concluded with an LOI | Schizophrenia |
| Strensiq (asfotase alfa) | Alexion Pharma GMBH | Concluded with an LOI | pediatric-onset hypophosphatasia |
| Narcan (naloxone hydrochloride) | Adapt Pharma Operations Limited | Concluded with an LOI | Opioid Overdose |
| Methadose (methadone hydrochloride) | Mallinckrodt Canada ULC | Concluded without agreement | Opioid Dependence |
| Metoject (methotrexate) | Medexus Pharmaceuticals, Inc. | Concluded with an LOI | Rheumatic Conditions |
| Copaxone (glatiramer acetate) | Teva Canada Limited | Concluded without agreement | Clinically Isolated Syndrome |
| Botox (onabotulinumtoxin a) | Allergan Inc. | Concluded with an LOI | Multiple Indications |
| Faslodex (fulvestrant) | AstraZeneca Canada Inc. | Concluded without agreement | Locally Advanced or Metastatic Breast Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Classic Hodgkin's Lymphoma |
| Onivyde (irinotecan liposome) | Shire Pharma Canada ULC | Concluded without agreement | Metastatic Pancreatic Cancer |
| Yervoy/Opdivo (nivolumab/ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Glatect (glatiramer acetate) | Pendopharm, a division of Pharmascience Inc. | Concluded with an LOI | Multiple Sclerosis, relapsing - remitting |
| Cerdelga (eliglustat) | Sanofi Genzyme Canada | Concluded without agreement | Gaucher disease |
| Ocaliva (obeticholic acid) | Intercept Pharma Canada | Concluded with an LOI | Primary biliary cholangitis |
| Caprelsa (vandetanib) | Sanofi Genzyme Canada | Concluded with an LOI | Medullary Thyroid Cancer |
| Erelzi (etanercept) | Sandoz Canada Inc. | Concluded with an LOI | Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis |
| Zinbryta (daclizumab beta) | Biogen Canada Inc. | Negotiations were not pursued | Multiple Sclerosis, relapsing |
| Darzalex (daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma |
| Lixiana (edoxaban) | Servier Canada Inc. | Concluded with an LOI | Venous thromboembolism, treatment and recurrence prevention |
| Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Lancora (ivabradine) | Servier Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Fibristal (ulipristal acetate) | Allergan Inc. | Concluded without agreement | Uterine fibroids (signs and symptoms) - 2nd cycle pre-surgery |
| Mictoryl (propiverine hydrochloride) | Duchesnay Inc. | Concluded without agreement | Overactive bladder |
| Kevzara (sarilumab) | sanofi-aventis Canada Inc. | Concluded without agreement | Rheumatoid Arthritis |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Actikerall (fluorouracil/salicylic acid) | Cipher | Concluded with an LOI | Hyperkeratotic actinic keratosis |
| Stelara (ustekinumab) | Janssen Inc. | Concluded without agreement | Crohn's disease |
| Lixiana (edoxaban) | Servier Canada Inc. | Concluded with an LOI | Non-valvular atrial fibrillation, prevention of stroke and systemic embolism |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Pediatric Acute Lymphoblastic Leukemia (ALL) |
| Ravicti (glycerol phenylbutyrate) | Horizon Therapeutics Ireland DAC | Concluded with an LOI | Urea cycle disorders |
| Hemangiol (propranolol oral solution) | Pierre Fabre | Concluded with an LOI | Infantile hemangioma |
| Brivlera (brivaracetam) | UCB Canada Inc. | Concluded with an LOI | Epilepsy, partial-onset seizures |
| Ibrance (palbociclib) | Pfizer Canada ULC | Concluded with an LOI |